Findings showed pegvaliase reduced mean blood Phe levels from baseline by 49.7% compared with 0.3% with diet only at week 72.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company's PALYNZIQ® (pegvaliase-pqpz) supplemental ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback